Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy

Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy in patients undergoing elective angiography with or without percutaneous coronary intervention: a single center prospective randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180417039347N1

Enrollment

250

Registered

2018-11-20

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy. Other complications following infusion, transfusion and therapeutic injection

Interventions

Intervention 1: Intervention group: Group II was received Atorvastatin 80mg before coronary procedures (Atorvastatin 80 mg). Intervention 2: Intervention group: Group III was administered N-acetylcys

Eligibility

Sex/Gender

All

Age

21 Years to No maximum

Inclusion criteria

Inclusion criteria: Eligible patients include individuals older than 21 years old abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) =1.1 mg/dL) Undergoing elective cardiac catheterization with or without PCI

Exclusion criteria

Exclusion criteria: Patients with end-stage renal failure (glomerular filtration rate (GFR) = 15 mL/min), history of previous dialysis pulmonary edema emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ), exposure to contrast within previous two days ago before procedure allergies to contrast media, contraindication to statins liver disease

Design outcomes

Primary

Measure	Time frame
Serum creatinine level altration. Timepoint: Serum creatinine levels are measured on the first day (day before the procedure) and 48 hours after exposure. Method of measurement: creatinine test.	—

Secondary

Measure	Time frame
Incidence of CIN. Timepoint: 48 h post exposure contrast media. Method of measurement: creatinine test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Keshtkar

Zahedan University of Medical Sciences

s.keshtkar20@gmail.com+98 54 3329 5717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026